Durect Corp
DRRX
Market Cap$18.56M
Close$
$0.11
84.6% downside
Current Fair Value
84.6% downsideOvervalued by 84.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.56 Million |
|---|---|
| Enterprise Value | $9.76 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.27 |
| Beta | 0.89 |
| Outstanding Shares | 31,041,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.23 |
|---|---|
| PEG | -5.29 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.19 |
| Enterprise Value to EBIT | -0.5 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Durect Corp
CEO: James Brown DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. ...